

Alain Martin, Ph. D - CEO & Director

Dr. Martin is the inventor for the clinical applications of N115 for the treatment of sinus and pulmonary diseases which is an all-natural anti-inflammatory agent found in the human body.

Dr Martin was responsible for the design and completion of 19 Phase I, II, III FDA human clinical trials, that demonstrated the ability of N115 to reduce inflammation, oxygen radicals and inflammatory cytokines including IL-6, a cause of the cytokine storm in patients with an active COVID-19 infection. N115 successfully treated the symptoms in long COVID (hypoxemia (low SaO₂), fatigue, coughing/sneezing, trouble breathing, body aches, headaches and pulmonary fibrosis while increasing lung functions, increasing the synthesis of NO, and increasing SaO₂ levels in thousands of patients including patients with varying lung diseases like COPD, Pulmonary Fibrosis (PF), Cystic Fibrosis, Allergic Rhinitis, Sinusitis and Influenza infected patients.

In addition to serving as EmphyCorp CEO, Dr. Martin is responsible for the scientific and business development of the technology and all licensing associated with its development. Dr. Martin, who has 40 years of experience in the biotechnology industry, previously served as Senior Manager of Research and Development for the Consumer Products Division of Warner-Lambert Company. He was responsible for the creation, development, and licensing of various technologies that fostered the growth of Warner-Lambert's \$2 billion Consumer Products Division. Dr. Martin created technologies that enhanced the penetration of therapeutic agents and enhanced the healing of damaged tissues and organs.

Dr. Martin's many contributions in the area of product innovation and development have given rise to 36 U.S. and numerous global patents for nasal and lung sprays and skincare/topical/injectibles for the treatment and faster healing of cuts, wounds, melanoma, inoperable tumors, tattoo revitalization, cancer drugs, post laser surgery healing, and several of which protect proprietary rights to products that have been and continue to be successfully commercialized.

Patented technologies developed by Dr. Martin are currently being used in six *Johnson & Johnson products that are generating approximately \$923 million in annual sales revenue.

Some of these patents protect products that include:

- Neosporin – (\$460 Million)
- Lubriderm – (\$89 Million)
- Cool Mint Listerine and three Schick products – (\$168 Million)

While at Warner-Lambert, Dr. Martin was the recipient of the President's Award for the creation of innovative new technologies.

As a member of the Board of Directors of MIT industrial consortium Dr. Martin helped to establish the overall business development strategy for commercializing MIT's intellectual property.

Dr. Martin holds four graduate degrees including two master's degrees, one from the University of Connecticut in Cell Physiology, and one from Rutgers University in Genetics and a PhD from the Rutgers School of Medicine and Dentistry where he completed his PhD degree in cell physiology after attending Yale University Graduate School.

*Warner-Lambert was acquired by Pfizer in 2000, and Pfizer sold Warner-Lambert's Consumer Health unit to Johnson & Johnson in 2001.